Amendments to the Claims:

Claim 1 (Currently Amended): An isolated glycoprotein comprising the human amino acid primary structure of CD55 and a tumor-specific N-linked glycostructure, wherein said glycoprotein has an apparent molecular weight of about 82 kD in sodium dodecyl sulfate polyacrylamide gel electrophoresis and is a glycoprotein present on adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201), but not on a normal cell.

Claims 2-3 (Canceled).

Claim 4 (Previously Presented): A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by size-exclusion chromatography.

Claims 5-41 (Canceled).

Claim 42 (Previously Presented): A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by anion-exchange chromatography.

Claim 43 (Previously Presented): The isolated glycoprotein of claim 1, wherein said glycoprotein, if present on a cell and bound by an antibody that is specific for said glycostructure, results in apoptosis of said cell.

Claim 44 (Canceled).

Claim 45 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in cleavage of cytokeratin 18 in said cell.

Claim 46 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in increased c-myc expression in said cell.

Claim 47 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in decreased topoisomerase IIα expression in said cell.

Claim 48 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure results in an increase in intracellular Ca^{2+} concentration in said cell.

Claim 49 (Previously Presented): The isolated glycoprotein of claim 43, wherein binding of said antibody to said glycostructure does not induce cleavage of poly(ADP-ribose)-polymerase in said cell.

Claim 50 (Currently Amended): An isolated glycoprotein comprising a section of a glycosylated human CD55 protein expressed by adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201), but not by a normal cell, wherein said glycosylated human CD55 protein has an apparent molecular weight of about 82 kD in sodium dodecyl sulfate polyacrylamide gel electrophoresis and wherein said section of said glycosylated human CD55 protein comprises a tumor-specific N-linked glycostructure.

Claim 51 (Previously Presented): The isolated glycoprotein of claim 50, wherein an antibody that specifically binds said tumor-specific N-linked glycostructure of said section, upon binding, induces apoptosis of a cell expressing said glycosylated human CD55 protein.

Claim 52 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure results in cleavage of cytokeratin 18 in said cell.

Claim 53 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure results in increased c-myc expression in said cell.

Claim 54 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure results in decreased topoisomerase IIα expression in said cell.

Claim 55 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure results in an increase in intracellular Ca^{2+} concentration in said cell.

Claim 56 (Previously Presented): The isolated glycoprotein of claim 51, wherein binding of said antibody to said glycostructure does not induce cleavage of poly(ADP-ribose)-polymerase in said cell.